Pembrolizumab
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma
Conditions
Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
Trial Timeline
Nov 2, 2021 → Jun 1, 2027
NCT ID
NCT05047094About Pembrolizumab
Pembrolizumab is a pre-clinical stage product being developed by Alpha Tau Medical for Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05047094. Target conditions include Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma.
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05047094 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma